{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:09:18Z","timestamp":1759777758022,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.mehy.2021.110756","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T17:26:25Z","timestamp":1641230785000},"page":"110756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Proposed mechanism for rare thrombotic events after use of some Covid-19 vaccines"],"prefix":"10.1016","volume":"159","author":[{"given":"Peter A.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.mehy.2021.110756_b0005","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110756_b0010","unstructured":"CDC Health Alert Network. Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 Vaccine, April 13 2021; CDCHAN-00442. https:\/\/emergency.cdc.gov\/han\/2021\/han00442.asp."},{"issue":"22","key":"10.1016\/j.mehy.2021.110756_b0015","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.mehy.2021.110756_b0020","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110756_b0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.thromres.2021.05.010","article-title":"Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination","volume":"203","author":"Douxfils","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.mehy.2021.110756_b0030","article-title":"Meta-analysis of risk of vaccine-induced thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine","author":"Chan","year":"2021","journal-title":"medRxiv preprint."},{"key":"10.1016\/j.mehy.2021.110756_b0035","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2516.2002.00633.x","article-title":"Rare coagulation deficiencies","volume":"8","author":"Peyvandi","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.mehy.2021.110756_b0040","unstructured":"European Medicines Agency. Summary of product characteristics Vaxzevria injection COVID-19 Vaccine (ChAdOx1-S [recombinant]). Approved by CHMP on 29 January 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (accessed on 07 May 2021)."},{"key":"10.1016\/j.mehy.2021.110756_b0045","unstructured":"European Medicines Agency. Summary of product characteristics COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]). Approved by the CHMP on 07 May 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-janssen-epar-product-information_en.pdf (accessed on 07 May 2021)."},{"issue":"7","key":"10.1016\/j.mehy.2021.110756_b0050","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.mehy.2021.110756_b0055","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.mehy.2021.110756_b0060","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and Ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mehy.2021.110756_b0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.mehy.2021.110756_b0070","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1128\/JVI.02562-08","article-title":"Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells","volume":"83","author":"Jonsson","year":"2009","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.mehy.2021.110756_b0075","doi-asserted-by":"crossref","first-page":"e1001142","DOI":"10.1371\/journal.ppat.1001142","article-title":"Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X","volume":"6","author":"Bradshaw","year":"2010","journal-title":"PLoS Pathog"},{"issue":"20","key":"10.1016\/j.mehy.2021.110756_b0080","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1128\/JVI.05382-11","article-title":"A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus\/FX complexes","volume":"85","author":"Duffy","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.mehy.2021.110756_b0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.mehy.2021.110756_b0090","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mehy.2021.110756_b0095","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1016\/S0021-9258(18)88991-8","article-title":"Tyrosine sulfation of yolk proteins 1, 2 and 3 in Drosophila melanogaster","volume":"260","author":"Baeuerle","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2021.110756_b0100","unstructured":"UniProtKB - P04133 (CAPSH_ADE05). https:\/\/www.uniprot.org\/uniprot\/P04133 (accessed on 28 April 2021)."},{"issue":"1","key":"10.1016\/j.mehy.2021.110756_b0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/bloodadvances.2016000877","article-title":"Polyphosphate\/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia","volume":"1","author":"Cines","year":"2016","journal-title":"Blood Adv"},{"issue":"02","key":"10.1016\/j.mehy.2021.110756_b0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0037-1613783","article-title":"Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice","volume":"83","author":"Dewerchin","year":"2000","journal-title":"Thromb Haemost"},{"issue":"01","key":"10.1016\/j.mehy.2021.110756_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-0038-1657520","article-title":"Inherited factor X deficiency: molecular genetics and pathophysiology","volume":"78","author":"Cooper","year":"1997","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mehy.2021.110756_b0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2141.2002.03486.x","article-title":"Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency","volume":"117","author":"Peyvandi","year":"2002","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.mehy.2021.110756_b0125","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.cub.2009.07.032","article-title":"Human Y chromosome base-substitution mutation rate measured by direct sequencing in a deep-rooting pedigree","volume":"19","author":"Xue","year":"2009","journal-title":"Curr Biol"},{"issue":"28","key":"10.1016\/j.mehy.2021.110756_b0130","doi-asserted-by":"crossref","first-page":"24535","DOI":"10.1074\/jbc.M111.241562","article-title":"Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate","volume":"286","author":"Zaiss","year":"2011","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.mehy.2021.110756_b0135","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc Nat Acad Sci"},{"issue":"2","key":"10.1016\/j.mehy.2021.110756_b0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1152\/physrev.00035.2013","article-title":"Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs","volume":"95","author":"Joyner","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.mehy.2021.110756_b0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccine","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2021.110756_b0150","unstructured":"Greinacher A, Selleng K, Wesche J, et al. Towards understanding ChAdOx1nCov-10 vaccine-induced immune thrombotic thrombocytopenia. Research Square 2021 (Preprint). DOI: 10.21203\/rs.3.rs-440461\/v1. https:\/\/www.researchsquare.com\/article\/rs-440461\/v1 (accessed on 04 May 2021)."},{"issue":"22","key":"10.1016\/j.mehy.2021.110756_b0155","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.mehy.2021.110756_b0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12250-020-00307-1","article-title":"Seroprevalence of neutralizing antibodies against six human adenovirus types indicates the low level of herd immunity in young children from Guangzhou, China","volume":"36","author":"Tian","year":"2021","journal-title":"Virologica Sinica"},{"issue":"2","key":"10.1016\/j.mehy.2021.110756_b0165","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110756_b0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbrc.2007.05.092","article-title":"Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity","volume":"359","author":"Du","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2021.110756_b0175","series-title":"Haemostasis and Thrombosis","first-page":"439","article-title":"Physiology and biochemistry of factor X","author":"James","year":"1994"},{"key":"10.1016\/j.mehy.2021.110756_b0180","series-title":"Production of plasma proteins for therapeutic use","first-page":"101","article-title":"Factor XIII and Factor X","author":"Feldman","year":"2013"},{"issue":"49","key":"10.1016\/j.mehy.2021.110756_bib181","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Scientific Advances"},{"issue":"22","key":"10.1016\/j.mehy.2021.110756_bib182","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721002759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721002759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:17Z","timestamp":1759692377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721002759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"alternative-id":["S0306987721002759"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110756","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposed mechanism for rare thrombotic events after use of some Covid-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110756"}}